The MarketReader Minute
đź’Š IBB Down as Biotech Faces Mixed Sentiment, FDA Concerns Weigh | Biotech Sector Insights
A positive start to the week was overshadowed by concerns following a major FDA rejection, as noted by a leading oncologist. Despite optimism around a gene therapy trial in Europe and lower-than-expected pharma tariffs, key holdings like GILD, AMGN, VRTX, BIIB, and BNTX declined.